Pictet Asset Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Pictet Asset Management’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.35M	Buy	200,275 +62,163	+45%	+$1.45M	0.01%	794
2026 Q1	$2.98M	Buy	138,112 +50,425	+58%	+$1.29M	﹤0.01%	844
2025 Q4	$2.51M	Buy	87,687 +74,528	+566%	+$1.91M	﹤0.01%	870
2025 Q3	$248K	Sell	13,159 -5,398	-29%	-$85.1K	﹤0.01%	1759
2025 Q2	$260K	Hold	18,557	–	–	﹤0.01%	1708
2025 Q1	$290K	Hold	18,557	–	–	﹤0.01%	1637
2024 Q4	$258K	Hold	18,557	–	–	﹤0.01%	1721
2024 Q3	$173K	Hold	18,557	–	–	﹤0.01%	1856
2024 Q2	$173K	Buy	+18,557	New	+$168K	﹤0.01%	1796

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Pictet Asset Management's ARQT Position: Q2 2026 in Review

Pictet Asset Management increased its Arcutis Biotherapeutics (ARQT) stake by 45% in Q2 2026, buying an estimated $1.45M and bringing the position to 200,275 shares worth $5.35M. The position accounts for 0.01% of the portfolio, ranked #794.

Pictet Asset Management first reported a position in ARQT in Q2 2024 and has held it in 9 quarters since. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

Pictet Asset Management held 200,275 shares of Arcutis Biotherapeutics worth $5.35M as of Q2 2026.
Pictet Asset Management bought 62,163 Arcutis Biotherapeutics shares in Q2 2026, an estimated $1.45M.
Arcutis Biotherapeutics made up 0.01% of Pictet Asset Management's portfolio in Q2 2026, its #794 holding.
Pictet Asset Management first reported a position in Arcutis Biotherapeutics in Q2 2024 and has held it in 9 quarters since.
272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.